10
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Acute diabetic neuropathy following improved glycaemic control: a case series and review

      research-article
      1 , 1 , 2 , 1 , 1 , 1
      Endocrinology, Diabetes & Metabolism Case Reports
      Bioscientifica Ltd
      Adult, Male, White, Ireland, Pancreas, Diabetes, Insulin, Diabetes mellitus type 2, Diabetic neuropathy*, Hyperglycaemia, Diabetic amyotrophy*, Diabetic mononeuritis*, Insulin neuyritis*, Oculomotor nerve palsy, Diabetes mellitus type 2, Hypotension, Leg pain, Weight loss, Myasthaenia, Hyperglycaemia, Vision - blurred, Ptosis, Diplopia, Fatigue, Polyuria, Polydipsia, Chest pain, Paraesthesia, Ophthalmoplegia, Muscle atrophy, T-reflex (absent) , Haemoglobin A1c, BMI, Glucose (blood), Electromyography, Nerve conduction study, Metformin, SGLT2 inhibitors, Pregabilin*, Insulin, Sulphonylureas, Gliclazide, Dapagliflozin, Neurology, Error in diagnosis/pitfalls and caveats, February, 2020

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Summary

          We present three cases of acute diabetic neuropathy and highlight a potentially underappreciated link between tightening of glycaemic control and acute neuropathies in patients with diabetes. Case 1: A 56-year-old male with poorly controlled type 2 diabetes (T2DM) was commenced on basal-bolus insulin. He presented 6 weeks later with a diffuse painful sensory neuropathy and postural hypotension. He was diagnosed with treatment-induced neuropathy (TIN, insulin neuritis) and obtained symptomatic relief from pregabalin. Case 2: A 67-year-old male with T2DM and chronic hyperglycaemia presented with left lower limb pain, weakness and weight loss shortly after achieving target glycaemia with oral anti-hyperglycaemics. Neurological examination and neuro-electrophysiological studies suggested diabetic lumbosacral radiculo-plexus neuropathy (DLPRN, diabetic amyotrophy). Pain and weakness resolved over time. Case 3: A 58-year-old male was admitted with blurred vision diplopia and complete ptosis of the right eye, with intact pupillary reflexes, shortly after intensification of glucose-lowering treatment with an SGLT2 inhibitor as adjunct to metformin. He was diagnosed with a pupil-sparing third nerve palsy secondary to diabetic mononeuritis which improved over time. While all three acute neuropathies have been previously well described, all are rare and require a high index of clinical suspicion as they are essentially a diagnosis of exclusion. Interestingly, all three of our cases are linked by the development of acute neuropathy following a significant improvement in glycaemic control. This phenomenon is well described in TIN, but not previously highlighted in other acute neuropathies.

          Learning points:
          • A link between acute tightening of glycaemic control and acute neuropathies has not been well described in literature.

          • Clinicians caring for patients with diabetes who develop otherwise unexplained neurologic symptoms following a tightening of glycaemic control should consider the possibility of an acute diabetic neuropathy.

          • Early recognition of these neuropathies can obviate the need for detailed and expensive investigations and allow for early institution of appropriate pain-relieving medications.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: not found

          Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes.

          Treatment-induced neuropathy in diabetes (also referred to as insulin neuritis) is considered a rare iatrogenic small fibre neuropathy caused by an abrupt improvement in glycaemic control in the setting of chronic hyperglycaemia. The prevalence and risk factors of this disorder are not known. In a retrospective review of all individuals referred to a tertiary care diabetic neuropathy clinic over 5 years, we define the proportion of individuals that present with and the risk factors for development of treatment-induced neuropathy in diabetes. Nine hundred and fifty-four individuals were evaluated for a possible diabetic neuropathy. Treatment-induced neuropathy in diabetes was defined as the acute onset of neuropathic pain and/or autonomic dysfunction within 8 weeks of a large improvement in glycaemic control-specified as a decrease in glycosylated haemoglobin A1C (HbA1c) of ≥2% points over 3 months. Detailed structured neurologic examinations, glucose control logs, pain scores, autonomic symptoms and other microvascular complications were measured every 3-6 months for the duration of follow-up. Of 954 patients evaluated for diabetic neuropathy, 104/954 subjects (10.9%) met criteria for treatment-induced neuropathy in diabetes with an acute increase in neuropathic or autonomic symptoms or signs coinciding with a substantial decrease in HbA1c. Individuals with a decrease in HbA1c had a much greater risk of developing a painful or autonomic neuropathy than those individuals with no change in HbA1c (P 4% points over 3 months the absolute risk of developing treatment-induced neuropathy in diabetes exceeded 80%. Treatment-induced neuropathy of diabetes is an underestimated iatrogenic disorder associated with diffuse microvascular complications. Rapid glycaemic change in patients with uncontrolled diabetes increases the risk of this complication.
            • Record: found
            • Abstract: not found
            • Article: not found

            Insulin neuritis: a case report

              • Record: found
              • Abstract: found
              • Article: not found

              Acute painful neuropathy induced by rapid correction of serum glucose levels in diabetic patients.

              We report on acute painful neuropathy following reduction of high serum glucose levels in six diabetic patients, aged 27-52 (5 males). Initial glucose levels ranging between 270 and 600 mg/dL decreased to 60-160 mg/dL following insulin, pharmacologic or dietary treatment. Four patients had long-standing untreated diabetes (3-5 years). All six patients experienced severe excruciating neuropathic pain 2-4 weeks after initiation of treatment. Pain was generalized in all, starting in the feet in 4 cases. Pain intensity prompted the use of combination therapy with various anti-neuropathic pain agents. Symptoms gradually improved in all patients, allowing discontinuation of symptomatic therapy within 3-8 months. We conclude that acute painful neuropathy can complicate the correction of high glucose levels in diabetic patients. Therefore, careful correction of glucose levels should be considered in patients with long-standing uncontrolled diabetes.

                Author and article information

                Journal
                Endocrinol Diabetes Metab Case Rep
                Endocrinol Diabetes Metab Case Rep
                EDM
                Endocrinology, Diabetes & Metabolism Case Reports
                Bioscientifica Ltd (Bristol )
                2052-0573
                26 February 2020
                2020
                : 2020
                : 19-0140
                Affiliations
                [1 ]Departments of Diabetes and Endocrinology Connolly Hospital Blanchardstown, Royal College of Surgeons in Ireland, Dublin, Ireland
                [2 ]Department of Neurology Mater Misericordiae University Hospital, Dublin, Ireland
                Author notes
                Correspondence should be addressed to N Siddique; Email: najiach@ 123456yahoo.com
                Article
                EDM190140
                10.1530/EDM-19-0140
                7077599
                32101524
                5734c6d4-9f08-4e6c-8091-0b79a6560566
                © 2020 The authors

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License..

                History
                : 19 December 2019
                : 14 January 2020
                Categories
                Adult
                Male
                White
                Ireland
                Pancreas
                Diabetes
                Insulin
                Diabetes Mellitus Type 2
                Diabetic Neuropathy*
                Hyperglycaemia
                Diabetic Amyotrophy*
                Diabetic Mononeuritis*
                Insulin Neuyritis*
                Oculomotor Nerve Palsy
                Diabetes mellitus type 2
                Hypotension
                Leg pain
                Weight loss
                Myasthaenia
                Hyperglycaemia
                Vision - blurred
                Ptosis
                Diplopia
                Fatigue
                Polyuria
                Polydipsia
                Chest pain
                Paraesthesia
                Ophthalmoplegia
                Muscle atrophy
                T-reflex (absent)
                Haemoglobin A1c
                BMI
                Glucose (blood)
                Electromyography
                Nerve conduction study
                Metformin
                SGLT2 inhibitors
                Pregabilin*
                Insulin
                Sulphonylureas
                Gliclazide
                Dapagliflozin
                Neurology
                Error in Diagnosis/Pitfalls and Caveats
                Error in Diagnosis/Pitfalls and Caveats

                adult,male,white,ireland,pancreas,diabetes,insulin,diabetes mellitus type 2,diabetic neuropathy*,hyperglycaemia,diabetic amyotrophy*,diabetic mononeuritis*,insulin neuyritis*,oculomotor nerve palsy,hypotension,leg pain,weight loss,myasthaenia,vision - blurred,ptosis,diplopia,fatigue,polyuria,polydipsia,chest pain,paraesthesia,ophthalmoplegia,muscle atrophy,t-reflex (absent) ,haemoglobin a1c,bmi,glucose (blood),electromyography,nerve conduction study,metformin,sglt2 inhibitors,pregabilin*,sulphonylureas,gliclazide,dapagliflozin,neurology,error in diagnosis/pitfalls and caveats,february,2020

                Comments

                Comment on this article

                Related Documents Log